Scancell Holdings plc has entered into a research collaboration agreement with BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer. The research collaboration will combine Scancell's Moditope immunotherapy platform and BioNTech's platform technology for high-throughput cloning and characterization of naturally selected T cell receptors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
85.85 USD | +1.36% |
|
+8.23% | -17.87% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.87% | 20.44B | |
+21.77% | 127B | |
+24.79% | 117B | |
+26.20% | 27.77B | |
-14.36% | 16.62B | |
-11.96% | 15.92B | |
-46.65% | 14.94B | |
+12.83% | 14.74B | |
+56.91% | 14.38B | |
+146.76% | 12.42B |
- Stock Market
- Equities
- BNTX Stock
- News BioNTech SE
- Scancell Holdings plc Enters into Research Collaboration Agreement with Biontech